Skip to main content
. 2015 Mar 18;10(3):e0118434. doi: 10.1371/journal.pone.0118434

Fig 3. Viremia and serum cytokine levels are reduced in VLP-treated mice.

Fig 3

(A) Serum from untreated or VLP-treated EBOV-infected mice was analyzed for viral plaque-forming activity. n = 7–8, two separate experiments. * p < 0.05. (B) Serum was collected from three groups of mice: uninfected, VLP-treated; EBOV-infected; and EBOV-infected, VLP-treated (24 hours after infection). Cytokine and chemokine levels were determined by using a cytometric bead array (CBA) flex set analyzing 21 cytokines and chemokines. n = 5–9 for EBOV-infected and EBOV-infected/VLP-treated groups (two separate experiments), n = 3 for VLP-treated, uninfected (one experiment). * p<0.05 between EBOV-infected and EBOV-infected/VLP-treated groups.